Patents by Inventor Pamela S. VANDERVERE-CAROZZA

Pamela S. VANDERVERE-CAROZZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KU INHIBITORS AND THEIR USE
    Publication number: 20220089577
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: March 24, 2022
    Inventors: John J. TURCHI, Navnath GAVANDE, Pamela S. VANDERVERE-CAROZZA
  • XPA inhibitor compounds and their use
    Patent number: 11207296
    Abstract: The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 28, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: John J. Turchi, Navnath Gavande, Pamela S. Vandervere-Carozza
  • Ku inhibitors and their use
    Patent number: 11098033
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 24, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: John J Turchi, Navnath Gavande, Pamela S. Vandervere-Carozza
  • KU INHIBITORS AND THEIR USE
    Publication number: 20200308154
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Application
    Filed: May 24, 2017
    Publication date: October 1, 2020
    Inventors: John J TURCHI, Navnath GAVANDE, Pamela S. VANDERVERE-CAROZZA
  • XPA INHIBITOR COMPOUNDS AND THEIR USE
    Publication number: 20200222367
    Abstract: The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
    Type: Application
    Filed: September 18, 2018
    Publication date: July 16, 2020
    Inventors: John J. TURCHI, Navath GAVANDE, Pamela S. VANDERVERE-CAROZZA